Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients
Phase of Trial: Phase IV
Latest Information Update: 22 Aug 2013
At a glance
- Drugs Axitinib (Primary) ; Everolimus (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 01 Dec 2012 Lead trial centre added as reported by Netherlands Trial Register record.
- 01 Dec 2012 New source identified and integrated (Netherlands Trial Register: NTR3710).
- 05 Jul 2012 New trial record